Skip to main content
Therese Mulvey, MD, Oncology, Boston, MA

Therese M. Mulvey MD FASCO

Hematologic Oncology


Physician

Join to view full profile
  • 55 Fruit StBoston, MA 02114

  • Phone+1 617-726-6550

Dr. Mulvey is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1990 - 1992
  • Tufts Medical Center
    Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1989
  • Tufts Medical Center
    Tufts Medical CenterResidency, Internal Medicine, 1985 - 1988
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 1985

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1987 - 2027
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2015
  • CMS Meaningful Use Stage 1 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2013-2014
  • CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2013-2014

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • High-Risk Breast Clinic Helps Deliver Specialized Care
    High-Risk Breast Clinic Helps Deliver Specialized CareAugust 31st, 2020
  • CDK 4/6 Inhibitor, Ribociclib, with Adjuvant Endocrine Therapy for ER-Positive Breast Cancer (LEADER)
    CDK 4/6 Inhibitor, Ribociclib, with Adjuvant Endocrine Therapy for ER-Positive Breast Cancer (LEADER)September 18th, 2017
  • Chemotherapy-Induced Cognitive and Brain Changes in Older Adults with Breast Cancer
    Chemotherapy-Induced Cognitive and Brain Changes in Older Adults with Breast CancerNovember 14th, 2014

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: